InvestorsHub Logo
Followers 21
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Tuesday, 02/11/2020 1:23:21 PM

Tuesday, February 11, 2020 1:23:21 PM

Post# of 1716
Noble Capital analyst Cosme Ordonez resumes coverage on TrovaGene (NASDAQ: TROV) with a Outperform rating and a price target of $23.00.

The analyst comments "We believe Trovagene's shares are depressed as they do not reflect the value of onvansertib, which in our view, could become the preferred treatment for CRC patients harboring KRAS mutations. In 2020, the company is slated to release additional results from ongoing Phase II clinical trials in CRC, prostate cancer and acute myeloid leukemia. We believe positive results from these trials could act as a catalyst for the shares.:
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDF News